Cantor Fitzgerald maintains overweight on TruBridge stock, $29 target

Published 15/04/2025, 12:42
Cantor Fitzgerald maintains overweight on TruBridge stock, $29 target

On Tuesday, Cantor Fitzgerald reaffirmed its confidence in TruBridge Inc (NASDAQ:TBRG), maintaining an Overweight rating and a price target of $29.00. The firm’s analyst, Sarah James, highlighted TruBridge’s unique position in the healthcare information technology (HCIT) market, focusing on rural hospitals where there is a competitive advantage in outsourcing for leverage and efficiency. According to InvestingPro data, the company has demonstrated strong momentum with a remarkable 183% return over the past year, while maintaining a healthy gross profit margin of 51%.

TruBridge’s revenue composition is shifting favorably, with Revenue Cycle Management (RCM) services expected to make up a larger portion of the company’s earnings. By 2024, RCM is projected to account for 63.7% of TruBridge’s revenue, up from 57.1% in 2023. This change is seen as beneficial in the current political climate. InvestingPro analysis reveals that while the company isn’t currently profitable, analysts expect positive earnings this year, with two analysts recently revising their earnings estimates upward.

The firm’s analyst expressed a positive outlook on TruBridge’s potential for growth through cross-selling strategies. Cantor Fitzgerald forecasts a substantial increase in RCM cross-sell bookings, projecting a growth rate of 142.5%. This optimism is based on the company’s ability to expand its client base within the niche market it serves. The company’s strong free cash flow yield and current ratio of 1.7 support its growth initiatives.

TruBridge has been recognized for its strategic focus on smaller, rural hospitals that benefit from external HCIT solutions. By providing specialized services in this sector, the company has established a strong market presence.

Cantor Fitzgerald’s reiteration of the Overweight rating and $29.00 price target reflects a steady confidence in TruBridge’s business model and its prospects for continued growth in the healthcare technology sector.

In other recent news, TruBridge Inc. reported a mixed fourth quarter for 2024. The company significantly missed earnings per share (EPS) expectations, posting -$0.38 compared to the forecast of $0.0049. However, TruBridge’s revenue slightly exceeded expectations, coming in at $87.36 million against a forecast of $84.35 million. Analysts have taken note of these developments, with Cantor Fitzgerald’s Sarah James upgrading the stock’s price target to $29, citing the company’s long-term growth potential and improved client acquisition figures. Meanwhile, Stephens analyst Jeff Garro raised the price target to $28, maintaining an Equal Weight rating, acknowledging TruBridge’s fiscal year 2024 performance that exceeded revenue expectations by 4% and achieved a 24% beat on EBITDA. Despite a 40% year-over-year decline in bookings, analysts anticipate that delayed deals will close in the first half of 2025, which could positively impact the company’s fiscal year 2025 guidance. TruBridge has set a revenue guidance range of $345 million to $360 million for 2025, aiming for mid-single-digit growth. The company’s strategic initiatives, including offshoring and cost-cutting measures, have contributed to its improved financial performance, marking a turnaround from previous losses to a 4% free cash flow margin for fiscal year 2024.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.